Table 1.

MIC for M. bovis BCG and mechanism of action of anti-mycobacterials used in the study.

Drug name	MIC (μM)	Primary target	Target pathway	Pathway category	Reference
Isoniazid, INH	1.5	Enoyl acyl carrier protein reductase InhA	Mycolic acid synthesis	Cell wall synthesis	Zhang, 2005
Ethambutol, EMB	3.1	Arabinosyltransferase EmbC	Arabinogalactan synthesis
BTZ043	0.003	Decaprenylphosphoryl-β-D-ribose oxidase DprE1			Makarov et al., 2009
Meropenem, MEM	12.5	Transpeptidase LdtMt2	Peptidoglycan synthesis		Kim et al., 2013
Bedaquiline, BDQ	0.26	F-ATP synthase	ATP synthesis	Oxidative phosphorylation	Andries et al., 2005
Carbonyl cyanide m-chlorophenyl hydrazine, CCCP	50	N.A.∗	Transmembrane proton gradient		Feng et al., 2015
Para-amino salicylic acid, PAS	3.1	Dihydrofolate reductase	Tetrahydrofolate synthesis	Cofactor synthesis	Zheng et al., 2013
Pyrazinoic acid, POA∗∗	1000	Aspartate decarboxylase PanD	Coenzyme A synthesis		Gopal et al., 2017
Moxifloxacin, MXF	0.4	DNA Gyrase	DNA topology	Nucleic acid synthesis	Zhang, 2005
Rifampicin, RIF	0.025	RNA Polymerase	RNA synthesis
Streptomycin, STR	0.2	16S rRNA	Protein synthesis	Protein synthesis

^∗Not applicable; CCCP is a protonophore and therefore has no primary macromolecular target. ^∗∗POA is the bioactive metabolite of prodrug pyrazinamide.